Zobrazeno 11 - 20
of 25
pro vyhledávání: '"Russell F. DeVore"'
Autor:
Leora Horn, Yu Shyr, Steven N. Wolff, Janessa Laskin, Alan Sandler, Russell F. DeVore, Zhiguo Zhao, David P. Johnson
Publikováno v:
Clinical lung cancer. 12(3)
Objectives Our study set out to determine the antitumor efficacy of carboplatin and irinotecan as assessed by response rate in persons with chemotherapy-naive extensive-disease, small-cell lung cancer (ED-SCLC). Secondary objectives included progress
Autor:
F. Anthony Greco, David H. Johnson, Patrick B. Murphy, Russell F. DeVore, John D. Hainsworth, Kenneth R. Hande
Publikováno v:
Cancer. 69:370-375
Etoposide is a schedule-dependent agent with greater activity against small cell lung cancer (SCLC) when a given dose is administered over several days compared with a 1-day administration of the same dose. In an attempt to capitalize on the schedule
Autor:
R. Neuhauss, Dieter K. Hossfeld, Martin Wolf, Wolf Achterrath, Kenneth R. Hande, Konrad Goerg, C. Goerg, Rudiger Pfab, Martin Reck, Masahiro Fukuoka, Klaus Havemann, Luigi Lenaz, James F. Bishop, Ulrich Gatzemeier, Noriyuki Masuda, Reiner Laumen, Philip Bonomi, Russell F. DeVore, Joachim von Pawel, Patrick B. Murphy, Anthony Greco, Kunihiko Kobayashi, Nagahiro Saijo, John D. Hainsworth, Kiyoyuki Furuse, Hisanobu Niitani, David H. Johnson
Publikováno v:
Oncology. 49:I-IV
Publikováno v:
Oncology. 49:57-62
Forty-two patients with unresectable non-small cell lung cancer (NSCLC) were treated with carboplatin (300, 350 or 400 mg/nr) and 21 days of oral etoposide (50 mg/m2/day). Thirty-three pati
Autor:
X. Jia, John V. Heymach, Steven Zhang, Bruce E. Johnson, David H. Johnson, Howard Safran, Russell F. DeVore, F. Yunus, Fadlo R. Khuri, H. M. Richards, P. M. De Porre, L. L. Schlabach
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 15(8)
Background: R115777 (tipifarnib, Zarnestra™) is a farnesyl transferase inhibitor that blocks the farnesylation of proteins involved in signal transduction pathways critical for cell proliferation and survival. This multicenter phase II study was co
Autor:
Philip Bonomi, James R. Jett, James D. Luketich, Russell F. DeVore, David H. Johnson, Tracey W. Dobbs, Lewis J. Cohen, Chandra P. Belani, David S. Ettinger
Publikováno v:
Europe PubMed Central
We examined the safety and efficacy of the docetaxel/cisplatin combination in patients with advanced, previously untreated NSCLC and evaluated changes in quality of life over time. Docetaxel was administered before cisplatin (both 75 mg/m2, 1-hour in
Autor:
David H. Johnson, B. Slovis, Lester Porter, Hak Choy, Kenneth R. Hande, K. Laporte, Russell F. DeVore, Yu Shyr, Paul Rosenblatt
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 34(3)
Purpose: Docetaxel, an active agent for non-small cell lung cancer (NSCLC), has demonstrated activity as a radiosensitizer in numerous pre-clinical studies. We conducted a phase I trial to determine the maximum-tolerated dose (MTD) and dose-limiting
Autor:
Chad Eustis, David H. Johnson, Hak Choy, David P. Carbone, Russell F. DeVore, John R. Roberts
Publikováno v:
The Annals of thoracic surgery. 72(3)
Neoadjuvant chemotherapy before resection is the standard of care for stage IIIA non-small cell lung cancer in many institutions. Further, neoadjuvant therapy is being studied in earlier stage lung cancer and may be applied more broadly in the future
Autor:
Nancy Mccullough, Peggy Krozely, Jonathan E. Dowell, Russell F. DeVore, Yu Shyr, John S. Rogers, David H. Johnson
Publikováno v:
Investigational new drugs. 19(1)
Purpose: To test the efficacy and safety ofthe novel antitumor agent MGI-114 (NSC 683863) in patientswith advanced non-small cell lung cancer (NSCLC) previouslytreated with chemotherapy. Methods: A two-stageaccrual design was used to ensure detection
Publikováno v:
Pharmacotherapy. 19(1)
Study Objective. To determine whether therapeutic drug monitoring can enhance administration of etoposide in patients with drug-responsive neoplasms. Design. Prospective, open-label study. Setting. University-affiliated hospital and cancer center. Pa